Literature DB >> 26089034

Montelukast attenuates lipopolysaccharide-induced cardiac injury in rats.

A E Khodir1, H A Ghoneim2, M A Rahim3, G M Suddek4.   

Abstract

This study investigates the possible protective effects of montelukast (MNT) against lipopolysaccharide (LPS)-induced cardiac injury, in comparison to dexamethasone (DEX), a standard anti-inflammatory. Male Sprague Dawley rats (160-180 g) were assigned to five groups (n = 8/group): (1) control; (2) LPS (10 mg/kg, intraperitoneal (i.p.)); (3) LPS + MNT (10 mg/kg, per os (p.o.)); (4) LPS + MNT (20 mg/kg, p.o.); and (5) LPS + DEX (1 mg/kg, i.p.). Twenty-four hours after LPS injection, heart/body weight (BW) ratio and percent survival of rats were determined. Serum total protein, creatine kinase muscle/brain (CK-MB), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH) activities were measured. Heart samples were taken for histological assessment and for determination of malondialdehyde (MDA) and glutathione (GSH) contents. Cardiac tumor necrosis factor α (TNF-α) expression was evaluated immunohistochemically. LPS significantly increased heart/BW ratio, serum CK-MB, ALP, and LDH activities and decreased percent survival and serum total protein levels. MDA content increased in heart tissues with a concomitant reduction in GSH content. Immunohistochemical staining of heart specimens from LPS-treated rats revealed high expression of TNF-α. MNT significantly reduced percent mortality and suppressed the release of inflammatory and oxidative stress markers when compared with LPS group. Additionally, MNT effectively preserved tissue morphology as evidenced by histological evaluation. MNT (20 mg/kg) was more effective in alleviating LPS-induced heart injury when compared with both MNT (10 mg/kg) and DEX (1 mg/kg), as evidenced by decrease in positive staining by TNF-α immunohistochemically, decrease MDA, and increase GSH content in heart tissue. This study demonstrates that MNT might have cardioprotective effects against the inflammatory process during endotoxemia. This effect can be attributed to its antioxidant and/or anti-inflammatory properties.
© The Author(s) 2015.

Entities:  

Keywords:  Lipopolysaccharide; cardiac injury; inflammation; montelukast; oxidative stress; rats

Mesh:

Substances:

Year:  2015        PMID: 26089034     DOI: 10.1177/0960327115591372

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  9 in total

1.  The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.

Authors:  Mahmoud M Said; Maarten C Bosland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-12-01       Impact factor: 3.000

2.  The Inhibition of LPS-Induced Oxidative Stress and Inflammatory Responses Is Associated with the Protective Effect of (-)-Epigallocatechin-3-Gallate on Bovine Hepatocytes and Murine Liver.

Authors:  Tianle Xu; Run Liu; Hao Zhu; Yu Zhou; Tianxu Pei; Zhangping Yang
Journal:  Antioxidants (Basel)       Date:  2022-05-06

Review 3.  Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Yaaser Q Almulaiky; Natália Cruz-Martins; Gaber El-Saber Batiha
Journal:  Eur J Pharmacol       Date:  2021-05-15       Impact factor: 4.432

4.  Effects of Active Components of Fuzi and Gancao Compatibility on Bax, Bcl-2, and Caspase-3 in Chronic Heart Failure Rats.

Authors:  Liqin Wang; Yu He; Yuyan Zhang; Huifen Zhou; Li Yu; Jiehong Yang; Haitong Wan
Journal:  Evid Based Complement Alternat Med       Date:  2016-12-08       Impact factor: 2.629

5.  Prototheca zopfii isolated from bovine mastitis induced oxidative stress and apoptosis in bovine mammary epithelial cells.

Authors:  Muhammad Shahid; Jian Gao; Yanan Zhou; Gang Liu; Tariq Ali; Youtian Deng; Naveed Sabir; Jingliang Su; Bo Han
Journal:  Oncotarget       Date:  2017-05-09

Review 6.  The Role of iRhom2 in Metabolic and Cardiovascular-Related Disorders.

Authors:  Ramasatyaveni Geesala; Priya D Issuree; Thorsten Maretzky
Journal:  Front Cardiovasc Med       Date:  2020-11-24

7.  Montelukast induces beneficial behavioral outcomes and reduces inflammation in male and female rats.

Authors:  Ira S Rostevanov; Batya Betesh-Abay; Ahmad Nassar; Elina Rubin; Sarit Uzzan; Jacob Kaplanski; Linoy Biton; Abed N Azab
Journal:  Front Immunol       Date:  2022-09-06       Impact factor: 8.786

8.  The in vitro effect of lipopolysaccharide on proliferation, inflammatory factors and antioxidant enzyme activity in bovine mammary epithelial cells.

Authors:  Huiyu Shi; Yongmei Guo; Yang Liu; Binlin Shi; Xiaoyu Guo; Lu Jin; Sumei Yan
Journal:  Anim Nutr       Date:  2016-03-24

9.  Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury.

Authors:  Shiyun Pu; Qinhui Liu; Yanping Li; Rui Li; Tong Wu; Zijing Zhang; Cuiyuan Huang; Xuping Yang; Jinhan He
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.